Scarica l'app Stockscreener
6.40
9.59%
0.56
Dopo l'orario di chiusura:
6.51
0.11
+1.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$5.84
Aprire:
$6.11
Volume 24 ore:
74.81M
Relative Volume:
2.87
Capitalizzazione di mercato:
$2.56B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-4.129
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
+21.21%
1M Prestazione:
+27.24%
6M Prestazione:
-6.98%
1 anno Prestazione:
-15.90%
Intervallo 1D:
$6.03
$7.15
Intervallo di 1 settimana:
$5.13
$7.15
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
6.40 | 2.29B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals Surges 58.77% in Trading Volume Reaching 207th Position in Market Rankings - AInvest
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX) - FinancialContent
What analysts say about Recursion Pharmaceuticals Inc. stockFree Consultation - Autocar Professional
Recursion Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment - Nasdaq
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Price Surge - Nasdaq
Recursion Pharmaceuticals Surges 5.8%: Will Momentum Continue? - AInvest
Why Is Recursion Pharma Stock Surging On Monday? - Benzinga
Recursion Pharmaceuticals Stock Soars Amid Investor Optimism - TipRanks
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - Insider Monkey
Recursion Bets On AI Drug Discovery Despite Volatile Year - Finimize
Recursion Pharmaceuticals Inc. Stock Analysis and ForecastExtraordinary performance - Autocar Professional
What drives Recursion Pharmaceuticals Inc. stock priceHigh-octane gains - PrintWeekIndia
Here's Why Shares in Recursion Pharmaceuticals Surged Today - AOL.com
Recursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last Month - Yahoo Finance
Recursion Pharmaceuticals Experiences Elevated Call Volume and Implied Volatility. - AInvest
Recursion Pharmaceuticals (RXRX) Is Up 10.6% After Expanding AI Partnerships and Acquiring Exscientia - simplywall.st
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Recursion Pharmaceuticals Surges to 360th in Market Rankings with $312 Million Trading Volume - AInvest
Is Recursion Pharmaceuticals Inc. a good long term investmentExponential return rates - jammulinksnews.com
Recursion Pharmaceutical’s Latest Acquisition: A Game Changer? - timothysykes.com
Why Did Recursion Soar 12%? - timothysykes.com
10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey
Recursion Pharmaceuticals Soars After Strategic Acquisition - StocksToTrade
Why Recursion Pharmaceuticals Stock is Climbing - TipRanks
Recursion Pharmaceuticals Acquires Full Rights to REV102, Bolstering Stock Performance - timothysykes.com
Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts - MSN
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Yahoo.co
Recursion Pharmaceuticals Sees Elevated Call Volume and Implied Volatility - AInvest
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail
With 68% institutional ownership, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a favorite amongst the big guns - simplywall.st
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - MSN
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. - The Motley Fool
(RXRX) Technical Data - news.stocktradersdaily.com
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Recursion Pharma Surges: An Unexpected 12% Jump - StocksToTrade
Recursion Pharmaceuticals: Leveraging AI and Strategic Partnerships to Tackle Rare Diseases - AInvest
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - Yahoo Finance
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
RXRX: Market Moves and Future Projections - timothysykes.com
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):